|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- May 28, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Affiris AG, of Vienna, Austria, said its atherosclerosis vaccine development program is receiving undisclosed financial support from the European Union's EuroTrans-BIO call. The project -- known as CETP Vaccine (ETB-2008-28) -- is based on the company's AFFITOME technology and is being conducted with EMC microcollections GmbH, of Tubingen, Germany. The aim of atherosclerosis vaccination is to increase the amount of good high density lipoprotein cholesterol in the blood to reduce the occurrence of harmful fatty deposits in the arteries, and Affiris is targeting CETP (cholesterol ester transfer protein).
Agios Pharmaceuticals, of Cambridge, Mass., appointed David ...